GFM
TRDA icon

GF Fund Management’s Entrada Therapeutics TRDA Stock Holding History

GF Fund Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.98K Sell
812
-40
-5% -$384 ﹤0.01% 564
2026
Q1 		$10.8K Buy
852
+101
+13% +$1.16K ﹤0.01% 554
2025
Q4 		$7.72K Sell
751
-56
-7% -$472 ﹤0.01% 600
2025
Q3 		$4.68K Sell
807
-151
-16% -$883 ﹤0.01% 611
2025
Q2 		$6.44K Hold
958
– – ﹤0.01% 611
2025
Q1 		$8.66K Buy
958
+173
+22% +$2.16K ﹤0.01% 582
2024
Q4 		$13.6K Buy
+785
New +$14.2K ﹤0.01% 508

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

GF Fund Management's TRDA Position: Q2 2026 in Review

GF Fund Management reduced its Entrada Therapeutics (TRDA) stake by 4.7% in Q2 2026, selling an estimated $384 and leaving 812 shares worth $5.98K. The position accounts for ﹤0.01% of the portfolio, ranked #564.

GF Fund Management first reported a position in TRDA in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.6K in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • GF Fund Management held 812 shares of Entrada Therapeutics worth $5.98K as of Q2 2026.
  • GF Fund Management sold 40 Entrada Therapeutics shares in Q2 2026, an estimated $384.
  • Entrada Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #564 holding.
  • GF Fund Management first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Entrada Therapeutics position peaked at $13.6K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.